false
0001799011
0001799011
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 12, 2026
| LUCID
DIAGNOSTICS INC. |
| (Exact
Name of Registrant as Specified in Charter) |
| Delaware |
|
001-40901 |
|
82-5488042 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 360
Madison Avenue, 25th Floor, New
York, New
York |
|
10017 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (917) 813-1828
| N/A |
| (Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, Par Value $0.001 Per Share |
|
LUCD |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
November 12, 2026, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for
its fiscal quarter ended September 30, 2026 and providing a business update. A copy of the press release is attached to this report as
Exhibit 99.1 and is incorporated herein by reference.
Item
7.01. Regulation FD Disclosure.
The
disclosure set forth under Item 2.02 is incorporated herein by reference.
The
information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of
the Company, except as shall be expressly set forth by specific reference in such document.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits:
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press release. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Dated:
November 12, 2026 |
LUCID
DIAGNOSTICS INC. |
| |
|
|
| |
By:
|
/s/
Dennis McGrath |
| |
|
Dennis
McGrath |
| |
|
Chief
Financial Officer |
Exhibit
99.1
Lucid
Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
EsoGuard®
now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume
to start the fourth quarter
Conference
call and webcast to be held today, November 12, at 8:30 AM EST
NEW
YORK, November 12, 2026 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage,
cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM) (“PAVmed”), today provided a business
update and reported financial results for the third quarter ended September 30, 2026.
Conference
Call and Webcast
The
webcast will take place on Thursday, November 12, 2026, at 8:30 AM EST and will be accessible in the investor relations section of the
Company’s website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial
1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference
call name “Lucid Diagnostics Business Update” to join.
Following
the conclusion of the conference call, a replay will be available for 30 days in the investor relations section of the Company’s
website at luciddx.com.
Business
Highlights
“Medicare
is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking
test,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “This breakthrough represents
a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial
acceleration and revenue growth.”
“Our
pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors,”
Dr. Aklog added. “Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution.
Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity
with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating
this early momentum into revenue growth. What has been a marathon is now a sprint.”
Highlights
from the third quarter and recent weeks:
| ● | Received
first Medicare payments for the EsoGuard® Esophageal DNA Test in
October. Lucid began submitting claims in late September after meeting with medical directors
at Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over Lucid’s
Texas laboratory, and providing a clinical evidence dossier incorporating their feedback.
Lucid has consistently received payments on these claims at EsoGuard’s established
Clinical Laboratory Fee Schedule rate of $1,938.01 per test. This Medicare coverage through
claim-by-claim adjudication is independent of the pending MolDX Local Coverage Determination
(LCD) reconsideration for EsoGuard. |
| ● | Immediately
and aggressively repositioned commercial efforts to expand EsoGuard testing among at-risk
Medicare beneficiaries, representing approximately half of the patients recommended for esophageal
precancer testing by professional society guidelines. |
| ● | Performed
2,871 EsoGuard tests and recognized revenue of $1.2 million in 3Q26. October was a record
month for EsoGuard test volume, with more than 1,800 tests. More than 50,000 EsoGuard tests
have been performed since launch. |
| ● | Held
a formal meeting with CMS leadership on the pending MolDX LCD reconsideration for EsoGuard.
The discussion reinforced Lucid’s confidence that the delay is attributable to an administrative
backlog. Lucid expects the draft LCD to be published as that backlog begins to clear. |
| ● | Continued
to expand commercial coverage through the Concert EsoGuard coverage policy, with a
total of five Concert client health plans, including the three previously reported, expected
to have formally adopted it by year-end. |
| ● | Launched
Lucid’s first two U.S. Department of Veterans Affairs (VA) programs, with a
robust pipeline of additional VA centers behind them. Lucid continues to expect the VA to
be a meaningful long-term contributor to its commercial activity and revenue. |
| ● | Announced
billing and coding milestones, including a new Category III CPT code for EsoCheck
cell collection and a proposed ICD-10 diagnosis code for positive EsoGuard results, which
will make EsoGuard and EsoCheck easier to bill, track and integrate into clinical practice. |
| ● | Announced
publication of an 11,991-patient real-world EsoGuard study, the largest peer-reviewed
study of nonendoscopic esophageal precancer testing to date. Sampling with the EsoCheck®
Esophageal Cell Collection Device was successful in 95% of patients and averaged less
than two minutes. The procedure was well tolerated, with no reported device-related adverse
events and consistent performance across operators, including newly trained personnel. |
| ● | The
American Gastroenterological Association (AGA) released its draft Barrett’s esophagus
guidelines for public comment. The draft names EsoGuard and EsoCheck as an alternative to
endoscopy, with high certainty of evidence. EsoGuard is the only commercially available
test cited. |
| ● | Strengthened
balance sheet with a $15.0 million private placement to existing long-term investors. |
Financial
Results
| ● | For
the three months ended September 30, 2026, EsoGuard related revenues were $1.2 million. Operating
expenses were approximately $13.5 million, which included stock-based compensation expenses
of $1.5 million. GAAP net loss attributable to common stockholders was approximately $6.7
million, or $(0.03) per common share. |
| ● | As
shown below and for the purpose of illustrating the effect of stock-based compensation and
other non-cash income and expenses on the Company’s financial results, the Company’s
non-GAAP adjusted loss for the three months ended September 30, 2026 was approximately $10.6
million or $(0.06) per common share. |
| ● | Lucid
had cash and cash equivalents of $18.0 million as of September 30, 2026, compared to $34.7
million as of December 31, 2025. Subsequent to quarter end, Lucid closed a $15.0 million
Series C Convertible Preferred Stock financing. |
| ● | The
unaudited financial results for the three and nine months ended September 30, 2026, were
filed with the SEC on Form 10-Q on November 12, 2026, and available at www.luciddx.com or
www.sec.gov. |
Lucid Non-GAAP Measures
| |
● |
To
supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management
provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include
net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA
for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of
EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP. |
| |
● |
Non-GAAP
financial measures are presented with the intent of providing greater transparency to the information used by us in our financial
performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information
to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical
financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not
intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to,
the most directly comparable GAAP financial measures. |
| |
● |
Non-GAAP
financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further
information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management
and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business
outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the
reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value
of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance.
In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods. |
| |
● |
A
reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for
the three and nine months ended September 30, 2026, and 2025 are as follows: |
| (in thousands except per-share amounts) | |
For the three months ended September 30, | | |
For the nine months ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Revenue | |
$ | 1,203 | | |
$ | 1,211 | | |
$ | 3,932 | | |
$ | 3,202 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses | |
| 13,479 | | |
| 12,970 | | |
| 41,122 | | |
| 38,831 | |
| Other (Income) expense, net | |
| (5,599 | ) | |
| (1,362 | ) | |
| (4,917 | ) | |
| 6,115 | |
| Net Loss | |
| (6,677 | ) | |
| (10,397 | ) | |
| (32,273 | ) | |
| (41,744 | ) |
| Net income (loss) per common share, basic and diluted | |
$ | (0.03 | ) | |
$ | (0.10 | ) | |
$ | (0.26 | ) | |
$ | (0.59 | ) |
| Net loss attributable to common stockholders | |
| (6,677 | ) | |
| (10,397 | ) | |
| (45,020 | ) | |
| (54,303 | ) |
| Preferred Stock dividends and deemed dividends | |
| — | | |
| — | | |
| 12,747 | | |
| 12,559 | |
| Net income (loss) as reported | |
| (6,677 | ) | |
| (10,397 | ) | |
| (32,273 | ) | |
| (41,744 | ) |
| Adjustments: | |
| | | |
| | | |
| | | |
| | |
| Depreciation and amortization expense1 | |
| 226 | | |
| 220 | | |
| 671 | | |
| 663 | |
| Interest expense, net2 | |
| (58 | ) | |
| (99 | ) | |
| (195 | ) | |
| (260 | ) |
| EBITDA | |
| (6,509 | ) | |
| (10,276 | ) | |
| (31,797 | ) | |
| (41,341 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Other non-cash or financing related expenses: | |
| | | |
| | | |
| | | |
| | |
| Stock-based compensation expense3 | |
| 1,451 | | |
| 1,152 | | |
| 4,555 | | |
| 3,326 | |
| Operating expenses issued in stock1 | |
| — | | |
| 87 | | |
| 57 | | |
| 234 | |
| Change in FV convertible debt2 | |
| (5,541 | ) | |
| (2,341 | ) | |
| (4,722 | ) | |
| 5,297 | |
| Equity issuance cost extinguishment2 | |
| — | | |
| 1,078 | | |
| — | | |
| 1,078 | |
| Non-GAAP adjusted (loss) | |
$ | (10,599 | ) | |
$ | (10,300 | ) | |
$ | (31,907 | ) | |
$ | (31,406 | ) |
| Basic and Diluted shares outstanding | |
| 190,945 | | |
| 108,176 | | |
| 171,575 | | |
| 92,131 | |
| Non-GAAP adjusted (loss) income per share | |
$ | (0.06 | ) | |
$ | (0.10 | ) | |
$ | (0.19 | ) | |
$ | (0.34 | ) |
1
Included in general and administrative expenses in the financial statements.
2
Included in other income and expenses.
3
Stock-based compensation (“SBC”) expense included in operating expenses is detailed as follows in the table below by
category within operating expenses for the non-GAAP Net operating expenses:
| (in thousands except per-share amounts) | |
For the three months ended September 30, | | |
For the nine months ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Cost of revenues | |
$ | 1,404 | | |
$ | 1,697 | | |
$ | 4,474 | | |
$ | 4,810 | |
| Stock-based compensation expense3 | |
| (14 | ) | |
| (43 | ) | |
| (142 | ) | |
| (152 | ) |
| Net cost of revenues | |
| 1,390 | | |
| 1,654 | | |
| 4,332 | | |
| 4,658 | |
| | |
| | | |
| | | |
| | | |
| | |
| Amortization of intangible assets | |
| 105 | | |
| 105 | | |
| 315 | | |
| 316 | |
| | |
| | | |
| | | |
| | | |
| | |
| Sales and marketing | |
| 5,252 | | |
| 4,291 | | |
| 16,029 | | |
| 12,367 | |
| Stock-based compensation expense3 | |
| (314 | ) | |
| (268 | ) | |
| (907 | ) | |
| (753 | ) |
| Net sales and marketing | |
| 4,938 | | |
| 4,023 | | |
| 15,122 | | |
| 11,614 | |
| | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 5,536 | | |
| 5,605 | | |
| 16,723 | | |
| 17,383 | |
| Depreciation expense | |
| (121 | ) | |
| (115 | ) | |
| (356 | ) | |
| (347 | ) |
| Operating expenses issued in stock | |
| — | | |
| (87 | ) | |
| (57 | ) | |
| (234 | ) |
| Stock-based compensation expense3 | |
| (949 | ) | |
| (718 | ) | |
| (3,024 | ) | |
| (2,060 | ) |
| Net general and administrative | |
| 4,466 | | |
| 4,685 | | |
| 13,286 | | |
| 14,742 | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
| 1,182 | | |
| 1,272 | | |
| 3,581 | | |
| 3,955 | |
| Stock-based compensation expense3 | |
| (174 | ) | |
| (123 | ) | |
| (482 | ) | |
| (361 | ) |
| Net research and development | |
| 1,008 | | |
| 1,149 | | |
| 3,099 | | |
| 3,594 | |
| | |
| | | |
| | | |
| | | |
| | |
| Total operating expenses | |
| 13,479 | | |
| 12,970 | | |
| 41,122 | | |
| 38,831 | |
| Depreciation and amortization expense | |
| (226 | ) | |
| (220 | ) | |
| (671 | ) | |
| (663 | ) |
| Operating expenses issued in stock | |
| — | | |
| (87 | ) | |
| (57 | ) | |
| (234 | ) |
| Stock-based compensation expense3 | |
| (1,451 | ) | |
| (1,152 | ) | |
| (4,555 | ) | |
| (3,326 | ) |
| Net operating expenses | |
$ | 11,802 | | |
$ | 11,511 | | |
$ | 35,839 | | |
$ | 34,608 | |
About
Lucid Diagnostics
Lucid
Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused
on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.
Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with
its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal
of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For
more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.
Forward-Looking
Statements
This
press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements
that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics’
management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks
and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics’ common
stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required
to advance Lucid Diagnostics’ products to regulatory submission; whether regulatory authorities will be satisfied with the design
of and results from Lucid Diagnostics’ clinical and preclinical studies; whether and when Lucid Diagnostics’ products are
cleared by regulatory authorities; market acceptance of Lucid Diagnostics’ products once cleared and commercialized; Lucid Diagnostics’
ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict
accurately and many of them are beyond Lucid Diagnostics’ control. In addition, new risks and uncertainties may arise from time
to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may
affect Lucid Diagnostics’ future operations, see Part I, Item 1A, “Risk Factors,” in Lucid Diagnostics’ most
recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A,
“Risk Factors” in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid
Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in
its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the forward-looking statements.
Investor
and Media Contact
Matt
Riley
Vice
President, Investor Relations
PAVmed
and Lucid Diagnostics
mjr@pavmed.com